<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627520</url>
  </required_header>
  <id_info>
    <org_study_id>2017-012-00CH1</org_study_id>
    <nct_id>NCT03627520</nct_id>
  </id_info>
  <brief_title>A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib</brief_title>
  <official_title>Single-center, Open and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 300 mg /100 μCi [14C] Sulfatinib in Chinese Adult Male Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open label and single-dose clinical trail, to explore the body mass
      balance and identify the major metabolites in Chinese adult male healthy volunteers after a
      single oral dose of [14C]Sulfatinib, to obtain the pharmacokinetic parameters of plasma and
      observe the safety of healthy volunteers after a single oral dose of [14C]Sulfatinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to determine the optimal time point for sample collection, this study will be
      divided into two stages: the first stage, two volunteers will be enrolled, the volunteers
      should stop collecting the corresponding samples by the investigators based on radioactive
      test results, safety results combined with the actual comprehensive situation. And in the
      second stage sample collection time for another four volunteers will be determined and
      adjusted according to the results of the first stage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is single centre, open label, single dose study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) of total radioactivity of [14C] Sulfatinib</measure>
    <time_frame>Measured from the 0 hour to 216 hours</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the Maximum observed plasma concentration (Cmax) of total radioactivity of [14C] Sulfatinib</measure>
    <time_frame>Measured from the 0 hour to 216 hours</time_frame>
    <description>Maximum observed concentration, occurring at Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the time to Cmax (peak time, Tmax) of total radioactivity of [14C] Sulfatinib</measure>
    <time_frame>Measured from the 0 hour to 216 hours</time_frame>
    <description>The time at which maximum plasma concentration (Cmax) is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate Half-life (t1/2) of total radioactivity of [14C] Sulfatinib</measure>
    <time_frame>Measured from the 0 hour to 216 hours</time_frame>
    <description>The time at which Half-life (t1/2) is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain mass balance data after a single oral dose of [14C] Sulfatinib</measure>
    <time_frame>Measured on the Day1 to Day15</time_frame>
    <description>Quantitative analysis of total radioactivity in the excretion of Sulfatinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To observe the safety of healthy volunteers after a single oral dose of [14C]Sulfatinib.</measure>
    <time_frame>Measured from the date signed ICF to within 15 days after the single dose</time_frame>
    <description>Adverse Event (AE) monitoring of [14C] Sulfatinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C]Sulfatinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]Sulfatinib</intervention_name>
    <description>300 mg Sulfatinib with 100 µCi [14C]</description>
    <arm_group_label>[14C]Sulfatinib</arm_group_label>
    <other_name>300 mg /100 μCi [14C] Sulfatinib, Sulfatinib, HMPL-012, Surufatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of written Informed Consent Form (ICF)

          2. Age of 18-50 (inclusive)；

          3. Body weight over 50 kg and body mass index (BMI) between 19-26 kg / m2 (inclusive)；

        Exclusion Criteria:

          1. Laboratory tests (blood tests, blood biochemical tests [fasting], coagulation tests,
             thyroid function tests, urinalysis, fecal occult blood) judged as clinically
             significant abnormal by investigators；

          2. Clinically significant abnormal ECG at screening and before screening；

          3. Hepatitis B surface antigen (HBsAg), e antigen (HBeAg) or hepatitis C antibody (HCV
             Ab) test positive；

          4. Human immunodeficiency virus (HIV) antibody positive；

          5. Treponema pallidum antibody positive.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Age of 18-50 (inclusive), Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke LI, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison Medipharma Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hutchison Medipharma Ltd.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.hmplglobal.com/en/sulfatinib/</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

